Dr. John Wang was graduated from China Pharmaceutical University (Nanjing, China) in 1982 and received his doctoral degree in pharmacology from "Mario Negri" Institute for Pharmacological Research in Milano, Italy. After returning from oversea, he had briefly worked in CPU as a Lecturer and directed PhD candidates. he had then worked briefly as a founding member of then National Center for New Drug Discovery and Development at Beijing.

John conducted his post-doc studies in the University of Arizona at Tucson from 1985-1988 and joined Mimotopes in Melbourne, Australia, one of the early biotech companies dedicated to develop combinatorial chemistry and HTS technology. In Mimotopes, John started as a senior scientist and became the Head of Biology. His responsibilities included small peptidic drug discovery through combinatorial chemistry and screening technologies and generation of polyclonal and monoclonal antibodies. During that period, John has traveled extensively in China and other Asian countries and regions including Hong Kong, Singapore, Taiwan, Japan and Korean to promote combinatorial and high throughput screening technologies

John joined the drug discovery group in Chiron Corporation in Emeryville, Califonia in 1995 after Chiron purchased Mimotpes. In addition to his regular scientific and managerial assignments, John had involved in Chiron’s expansion to Asian pacific regions and was assigned as a Coordinator of Asian Operation for Chiron, His responsibility included initiation, negotiation and supervision of collaborations with companies and institutes in Japan, Taiwan, Singapore, Hongkong and China.

Early 2006, Chiron was merged into Novartis. John has since been working in Novartis Emeryville campus. He has been working in biochemical lead discovery including early ADMET and novel assay technologies. John published over 40 research papers and chapters and is the author and co-author of several patents. John has been invited to speak to several international conferences.

John is currently a Board Director of Society of Biomolecule Sciences (SBS). His major contribution to the society includes being the Co-Program Chair of 2003 Annual Conference and Exhibition in Portland, OR. He also serves as the Chairman of Small Grant Review Committee for the society, as well as serve as the Board Liaison for membership and Award committee. He has twice received the "President Award" by the Society in 2002 and 2004, respectively.

John and few his colleagues also started an organization in 1998 to serve Chinese American Pharmaceutical Profession in the greater San Francisco area in 1998 that evolved to become CABS today. John is also closely working with other like-mined organizations throughout continental US, including CBA, CABA, SABPA, SCBA and Bayhelix.

Dr. Hu Li is a Manager of Biological Reagents and Assay Development in Molecular Discovery Research, GlaxoSmithKline. He has 12 years experience in the field of drug discovery focusing on small molecular candidates spanning from target identification to assay development and High Throughput Screening (HTS) and lead optimization. He has knowledge of a variety of assay technologies and hands-on experience in many assay platforms across target classes including kinases, GPCRs, Nuclear Receptors and novel enzymes. Dr. Li is a member of NIH study section of Assay Development for High Throughput Molecular Screening (R21) and HTS assay review (R03). Dr. Li obtained his PhD degree in biochemistry from Bryn Maws College in 1996, an MS degree in bioinorganic chemistry from Academia Sinica in 1989, and a BS degree in inorganic chemistry from Nanjing University in 1986. Dr. Li is a life-time member of SAPA.

Dr. Hui Li is currently research project leader and senior principal scientist at Pfizer Global Research & Development, La Jolla Laboratories, where he leads a multi-disciplinary discovery research team to identify clinical candidate(s) into human trial. His research interests include structure-based drug design, discovery and development of novel therapeutics in the field of oncology, anti-viral, diabetes and ophthalmology. Dr. Li obtained his B.S degree from Peking University and Ph.D in organic chemistry from University of California, San Diego. There he worked under the guidance of Professor K. C. Nicolaou on new synthetic technology development and the total synthesis of glycopeptide antibiotic Vancomycin. Dr. Li is a founding member of the Sino-American Biomedical & Pharmaceutical Association (SABPA) in 2002 and is currently serving as President and vice chairman of the board.

Leping Li is presently the Senior Director of Chemistry at Presidio Pharmaceuticals, Inc. a San Francisco-based biopharmaceutical company. Prior to joining Presidio, Leping held various positions at Amgen (and formerly Tularik), most recently as a Scientific Director in medicinal chemistry. Leping’s professional career also includes a 7-year stay at Abbott Laboratories. He graduated from Shandong University in 1983. The following year he came to the US on an exchange fellowship (Chemistry Graduate Program). He was trained as an organic chemist with a Ph.D. degree from Rice University and a postdoctoral fellowship at Stanford University. In his nearly 20 years’ professional career both with large and small companies, he has been involved in drug discovery programs from early lead identification to advanced clinical development stages across several therapeutic areas, including infectious diseases, cancers and metabolic disorders.

Daniel Liu received his B.Sc. in pharmacy and M. Sc in pharmaceutical chemistry from China Pharmaceutical University, Nanjing, China, and his PhD degree in pharmacology from University of Illinois, USA. Prior to joining pharmaceutical industry, he had more than 10 years of experiences researching in academic environment for drug research and development. He has contributed himself to Novartis, Pfizer, Sanofi-Synthelabo, Schering-Plough and Johnson&Johnson, respectively, in the field of global managements and operations of clinical studies since he received his PhD. He has extensive hands-on experiences in the designing, management and execution of global clinical trials, pharmacovigillance and assembly of regulatory files for the FDA NDA/IND submissions. Currently, he is Director of China Development at Medidata Solutions LLC. He is the member of the Provisional Advisory Council China of DIA, the member of standing board committee of “Organization of Chinese Clinical Research Professional”. He is the one of co-authors for two global GCP guidance books “Good Clinical Practice: A question and answer reference guide, May 2008” and “Computerized Systems in Clinical Research: Current Quality and Data Integrity Concepts, 2009”.

Dr. Mo is a senior scientist at MedImmune, the global biologics organization of AstraZeneca. He received his B.S. from Shanghai Medical University, M.S. from Peking Union Medical College, and PhD in Immunology and Microbiology from Wayne State University. He did his post-doctoral training in infectious diseases at Stanford University.

Dr. Yingfei Wei has an extensive experience in biotechnology and pharmaceutical industry both as a scientist and as a manager. She has published around thirty scientific papers, given many presentations at international conferences, and holds about forty patents. She is currently the Chief Scientific Officer of 3SBio, Inc., a NASDAQ listed Chinese Biotechnology company. From late 1998 to early 2004, Dr. Wei was with Bayer Biotech Research Division where she held a position as the Director of Cell and Analytical Biology. She was one of the exploratory research leaders there to design the R&D strategy and implement the research programs. She also led the effort of using the cell-based assays to perform drug screening, target identification and validation, and mechanism of action studies. Prior to joining Bayer, Dr. Wei was a Senior Scientist and Group Leader in Human Genome Sciences Inc. in Maryland (1993 – 1998). As one of the founding scientists at HGSI, Dr. Wei played key roles in the early establishment of the company. She was one of the scientists who discovered the HPNCC gene for colon cancer. Dr. Wei graduated from the Biology Department in Beijing University in 1983. She joined the CUSBEA program in 1983 and received her Ph.D. in Biochemistry from the University of California, Davis in 1990. She had her post-doctoral training in the Department of Molecular Cellular Toxicology in Harvard University from 1990 to 1993. Dr. Wei was the president of SAPA-West in the year 2002-2003.

Philip Zhang is Special Counsel in the Intellectual Property group and a member of the Cooley Godward Kronish Litigation department. Prior to joining Cooley, Dr. Zhang was Chief IP Counsel at Ensemble Discovery Corporation, a venture-backed biotechnology company engaged in research and development of novel therapeutic and diagnostic agents using proprietary DNA-Programmed ChemistryTM technology. Prior to joining Ensemble, Dr. Zhang was Patent Counsel at Genzyme Corporation, a leading biopharmaceutical company, where he handled IP matters for the company’s drug discovery and development units. Before joining Genzyme, Dr. Zhang was with Testa Hurwitz and Thibeault LLP. Dr. Zhang is a co-founder and current president of the Chinese American IP Law Association (CAIPLA). Dr. Zhang received his J.D. from Vanderbilt University Law School in 1999 and his Ph.D. in Organic Chemistry from Dartmouth College in 1995. He graduated from the University of Science & Technology of China (USTC) in 1986 with a B.S. in Chemistry. Dr. Zhang has extensive experience representing pharmaceutical, biotechnology, clean technology and medical devices companies, including advising clients on IP strategies, freedom-to-operate, licensing and patent preparation and prosecution. Dr. Zhang also helps clients with IP issues in R&D collaborations, venture funding, M&A and other transactions. Dr. Zhang regularly advises Asia-based clients with regard to various legal issues.

Dr. Guo-Liang is currently the Chairman and President of Epitomics, Inc. an emerging biotech company dedicated to the development of innovative next-generation monoclonal antibodies. Before starting Epitomics, he was the Senior Vice-President of Research and Development in Mendel Biotechnology Inc. Dr. Yu has broad technological and scientific experiences in many aspects of biotechnology. His interests cover genomics, molecular biology, genetics, immunology, cancer biology, and plant physiology and drug discovery. He is co-inventor and co-author of over 100 patents and scientific articles. Dr. Yu received Ph.D. degree in Molecular Biology from the University of California, Berkeley and B.S. degree in Biochemistry from Fudan University, China. Guo-Liang conducted his Post-doctoral training in Dr. Frederick Ausubel’s laboratory at the Harvard Medical School. Dr. Yu founded Chinese Biopharmaceutical Association (CBA) headquartered in Washington DC and is an Executive Member of several professional organizations in U.S and China.

Dr. Pei Yang has been working in bay area for eight years as scientist/staff scientist in different pharmaceutical companies, starting at Millennium Pharmaceuticals, Inc., then Nektar Therapeutics Inc. and Sunesis Pharmaceuticals Inc. He is now working at Portola Pharmaceuticals, Inc. He graduated from Nanjing University, and obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He also has several years’ working experience in analytical field and management in China. His major research interests include analytical development, method transfer/validation, preformulation/formulation, and controlled release of drug.

Naibo Yang is currently the Vice President of Business Development at BioChain Institute, Inc. His current job responsibilities include business development, licensing, reagent R&D, contract services, strategic growth etc. Prior to his current position, he was a Sr. Manager at MDS Analytical Technologies (Molecular Devices), in charge of application development for a number of high-throughput cell-based assay equipments; a Program Leader at Affymax Inc., for an ion channel drug discovery program; a Research Scientist at Exelixis Inc., responsible for molecular target research and cell-based efficacy & toxicity assays. Graduated with a Ph.D in neurophysiology from Thomas Jefferson University in 1996? his postdoc training was carried out in a Howard Hughes Medical Institute laboratory at Stanford University. His scientific expertise is in the fields of biophysics, neuroscience, in vitro cell-based assays, in vivo assays for preclinical studies etc. On the business side, he is experienced with marketing, pre/post sales supports, business development, in/out licensing etc.

Dr. Wang is a research scientist-turned biomedical communicator. She has substantial experience in developing different types of scientific documents, and she is skilled at crafting reader-oriented documents targeting audiences with different levels of scientific knowledge and varied backgrounds. Dr. Wang has studied and worked in three continents. She earned her Ph.D. in chemistry from the Institute of Chemistry, the Chinese Academy of Sciences in Beijing, China, in 1999. She subsequently received postdoctoral training in the biomedical field at Uppsala University in Sweden and the National Cancer Institute in the United States. During the past years, Dr. Wang has received extensive training in scientific and medical writing from the American Medical Writers Association (AMWA) and the National Association of Science Writers (NASW). She completed AMWA’s core certificate in pharmaceutical writing in 2007. In the same year, she founded the International Biomedical Communications, LLC, a company promoting effective biomedical communication and high-quality scientific writing. Dr. Wang is currently the principal science writer at the International Biomedical Communications. She also serves as the Vice President for Communications (2008-2009) at the Chinese Biopharmaceutical Association – USA (CBA).